researched 72 / 72 ・ last checked 2026-09-23 ENJA
Japan8United States8Canada8European Union8United Kingdom8China8Australia8Korea8Switzerland8

Advertising AtlasSwitzerland / Safety information

Safety information

Switzerland / Swissmedic

Every advertisement must contain at least a summary of the restrictions on use, the undesirable effects and the interactions, alongside the brand name, the active substances under their short designation (INN), the name and address of the marketing authorisation holder, at least one indication or use together with the dosage and route of administration, the dispensing category and a reference telling the reader that detailed information is in the published medicinal product information.

広告には少なくとも、使用制限・望ましくない作用・相互作用の要約を含めなければならず、あわせて製剤名、有効成分の略号名、承認取得者の名称と住所、少なくとも一つの効能または使用法と用量・投与方法、交付区分、詳細は公表された医薬品情報を参照すべき旨を記載しなければならない。

Note
Read in German on Fedlex. Art. 13 lit. a forbids professional advertising from using the word 'sicher' (safe) unless the information conveyed makes clear what that attribute refers to, and lit. b forbids stating that a medicine has no undesirable effects or is free of danger or harmless; Art. 22 lit. b applies an equivalent bar to advertising to the public (no guaranteed effect, no claim of no undesirable effects at all). Art. 8 (Erinnerungswerbung) allows the Art. 6 lit. d, e and h particulars to be omitted where the advertising makes no statement about use and merely indicates the therapeutic category, and Art. 9 restricts pure brand reminder advertising to the product name, the MAH name and the active substances.
Every cell carries a summary, a source and a date checked. Topics whose source has not been verified are left marked “not researched” rather than filled with plausible text. Directives and statutes bind as to the result; what applies in practice is national implementing law. This is a research aid, not legal advice.